C4 Therapeutics, Inc. Amortization of Debt Discount (Premium)
C4 Therapeutics, Inc. (CCCC) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2025-02-27
- C4 Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2023 was $405.00K, a 43.20% decline from fiscal 2022.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2022 was $713.00K, a 0.83% decline from fiscal 2021.
- C4 Therapeutics, Inc. amortization of debt discount (premium) for fiscal 2021 was $719.00K, a 75.79% increase from fiscal 2020.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | $0.00 derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $51.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $51.00K derived: sum of 3 quarters · filed 2025-02-27 | $229.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $51.00K derived: sum of 2 quarters · filed 2025-02-27 | $229.00K derived: sum of 3 quarters · filed 2025-02-27 | $405.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $229.00K derived: sum of 2 quarters · filed 2024-10-31 | $405.00K 10-Q · filed 2024-10-31 | $584.00K derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $354.00K 10-Q · filed 2024-08-01 | $533.00K derived: sum of 3 quarters · filed 2024-08-01 | $713.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $176.00K 10-Q · filed 2024-05-08 | $355.00K derived: sum of 2 quarters · filed 2024-05-08 | $535.00K derived: sum of 3 quarters · filed 2024-05-08 | $713.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $359.00K derived: sum of 2 quarters · filed 2024-02-22 | $537.00K derived: sum of 3 quarters · filed 2024-02-22 | $713.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $358.00K derived: sum of 2 quarters · filed 2023-11-01 | $534.00K 10-Q · filed 2023-11-01 | $713.00K derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $354.00K 10-Q · filed 2023-08-08 | $533.00K derived: sum of 3 quarters · filed 2023-08-08 | $713.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $176.00K 10-Q · filed 2023-05-04 | $355.00K derived: sum of 2 quarters · filed 2023-05-04 | $535.00K derived: sum of 3 quarters · filed 2023-05-04 | $713.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $359.00K derived: sum of 2 quarters · filed 2023-02-23 | $537.00K derived: sum of 3 quarters · filed 2023-02-23 | $719.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $358.00K derived: sum of 2 quarters · filed 2022-11-03 | $540.00K 10-Q · filed 2022-11-03 | $720.00K derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $178.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $360.00K 10-Q · filed 2022-08-04 | $540.00K derived: sum of 3 quarters · filed 2022-08-04 | $743.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $182.00K 10-Q · filed 2022-05-05 | $362.00K derived: sum of 2 quarters · filed 2022-05-05 | $565.00K derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $383.00K derived: sum of 2 quarters · filed 2022-02-24 | $409.00K 10-K · filed 2022-02-24 | |
| 2020-09-30 | $203.00K 10-Q · filed 2020-11-12 | $229.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $25.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |